Across TCGA pan-cancer cohorts, CEND1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CEND1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CEND1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CEND1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where CEND1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.261	0.606	.009	16	view →
CCRCC	DFS	Quartile	II,III,IV	0.846	0.338	.017	6	view →
HNSC	DFS	Median	All	0.477	0.821	.020	4	view →
LSCC	OS	Median	All	0.593	1.000	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CEND1 tumor-vs-normal RNA expression · all CEND1 data types